| 영문 | specific gravity | 한글 | 비중 |
|---|---|---|---|
| 설명 | 단위 부피당 질량. 소변의 비중은 소변의 농도를 반영한다. 예를 들어 소변의 비중이 크면, 콩팥의 물흡수가 원활히 이루어지고 있음을 나타낸다. |
||
| 영문 | carcinoembryonic antigen | 한글 | 암배아항원 |
|---|---|---|---|
| 설명 | 원래 태아의 장조직에서 정상적으로 존재하는 물질로 태아기 이후에는 존재하지 않는 물질이다. 그러나 위, 간, 허파 등의 암이 있는 경우에 성인에서도 존재한다. 이를 이용해서 암의 치료효과 판정이나 재발여부의 조사에 이용한다. |
||
| 영문 | antigen | 한글 | 항원 |
|---|---|---|---|
| 설명 | 특이한 면역반응을 일으킬 수 있는 어떠한 물질. 여기에서 말하는 특이한 면역반응이란 비특이적인 면역반응과는 반대되는 의미로 그 물질에 대해서 특이하게 반응할 수 있는 항체나 그 물질에 대해서 특이하게 반응할 수 있는 세포를 만드는 것을 말한다. |
||
| 영문 | bone marrow transplantation | 한글 | 골수이식 |
|---|---|---|---|
| 설명 | 환자의 병든 골수 대신 건강한 골수세포를 이식하는 처치-암치료에 방사선요법이나 화학요법을 썼을 경우 그 부작용으로 골수의 기능이 극도로 나빠졌을 때나 또는 백혈병의 경우에 면역요법으로 이용된다. 방법은 건강한 골수액을 채취하여 인산완충액을 섞은 링거액에 부유시켜 여과한 다음 정맥에 주사한다. 주입한 골수가 체내에 착상하여 번식하기 쉽게 할 목적으로 미리 X선을 조사하여 이식받는 환자의 항체기능을 억제해 둘 필요가 있다. 이 조작은 급성 방사능증을 일으키기 때문에 여러 가지 보호치료가 필요하다. 그러나 골수를 이식하면 급성 방사능증을 가볍게 넘길 수 있다고 하여 반대로 방사능을 대량으로 조사받은 사람에게 그 치료법으로 이용되기도 한다. 이식에는 스스로의 골수세포를 미리 채취해 놓고 후에 자신에게 주입하는 자가이식과 일란성쌍둥이의 한쪽에서 골수세포를 주입하는 동계이식 및 조직적합항원이 일치한 타인의 골수세포를 주입하는 동종이식이 있다. 대상병으로 백혈병, 재생불량빈혈, 선천면역결핍증 등이 있다. 일반적으로 강력한 면역억제제의 투여가 필요하다. 부작용으로서는 골수이식 후 이식편대숙주병, 기회감염 등이 있다. |
||
| 영문 | transplantation | 한글 | 이식(술) |
|---|---|---|---|
| 설명 | 같은 개체 또는 다른 개체로부터 떼어낸 조직의 이식을 말함. 이때, 이식물을 주는 쪽과 이식을 당하는 쪽의 서로간의 항원이 같아야 하며, 그렇지 않으면 거부반응이 일어난다. 하지만, 실제로 항원이 완전히 같은 경우는 드물며, 대개 이식을 받은 사람에게 계속적인 면역억제제를 투여함으로써 거부반응의 발생을 막는다. |
||
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TA | alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| TATA | Pribnow [box]; tumor-associated transplantation antigen |
| TSTA | Tumor-specific transplantation antigen |
|---|---|
| TATA | Tumor-associated transplantation antigen |
| T-antigen | Tumor antigen |
| GSA | Group-specific antigen |
| NCA | Non-specific cross-reacting antigen |
| tumour-specific transplantation antigens | Surface antigen's of DNA tumour virus-transformed cells, which elicit an immune rejection of the virus-free cells when transplanted into an animal that has been immunised against the specific cell-transforming virus. (05 Mar 2000) |
|---|---|
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| transplantation antigen | <immunology> Any antigen that is antigenically active in graft rejection. In practice the major histocompatibility complex and the H Y antigens and to a lesser extent minor histocompatibility antigens. (18 Nov 1997) |
| site-specific DNA-methyltransferase (adenine-specific) | <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on adenine residues in a specific short base sequence in the host cell DNA. The enzyme catalyses the methylation of DNA adenine in the presence of s-adenosyl-l-methionine to form DNA containing 6-methylaminopurine and s-adenosyl-l-homocysteine. Registry number: EC 2.1.1.72 (12 Dec 1998) |
| site-specific DNA methyltransferase (cytosine-specific) | <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on cytosine residues in a specific short base sequence in the host cell's DNA. The enzyme catalyses the methylation of DNA cytosine in the presence of s-adenosyl-l-methionine to form s-adenosyl-l-homocysteine and DNA containing 5-methylcytosine. Registry number: EC 2.1.1.73 (12 Dec 1998) |
| prostate-specific antigen | <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer. It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease. It is found in normal seminal fluid and produced by the prostatic epithelial cells. Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition. No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain. Acronym: PSA Registry number: EC 3.4.21.77 (22 Sep 2002) |
| species-specific antigen | Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on. (05 Mar 2000) |
| organ-specific antigen | A heterogenetic antigen with organ specificity; e.g., in addition to species-specific antigen, kidney of one species contains antigen that is identical to that in kidney of other species. Synonym: tissue-specific antigen. (05 Mar 2000) |
| tissue-specific antigen | A heterogenetic antigen with organ specificity; e.g., in addition to species-specific antigen, kidney of one species contains antigen that is identical to that in kidney of other species. Synonym: tissue-specific antigen. (05 Mar 2000) |
| tumour specific antigen | <immunology, oncology> Antigen on tumour cells detected by cell-mediated immunity. For virus transformed cells TSTA (unlike T antigen) is found to differ for different individual tumours induced by the same virus. May consist of fragments of T antigens exposed at the cell surface. (18 Nov 1997) |
| bone marrow transplantation | <oncology, procedure> Treatment in which healthy bone marrow replaces bone marrow that has been affected by a disease or by treatment for a disease. Acronym: BMT (12 May 1997) |
| bone transplantation | The grafting of bone from a donor site to a recipient site. (12 Dec 1998) |
| brain tissue transplantation | Transference of brain tissue, either from a foetus or from a born individual, between individuals of the same species or between individuals of different species. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|